Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Generation Bio Co. (GBIO)
NASDAQ:GBIO
Generation Bio (GBIO) Stock Price & Analysis
80 Followers
GBIO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.05 - $7.35
Previous Close$3.11
Volume3.08M
Average Volume (3M)115.69K
Market Cap
$205.04M
Enterprise Value-$28.47M
Total Cash (Recent Filing)$314.14M
Total Debt (Recent Filing)$80.63M
Price to Earnings (P/E)-1.5
Beta1.47
Next Earnings
Nov 14, 2023EPS Estimate
-$0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.08
Shares Outstanding65,928,503
10 Day Avg. Volume175,566
30 Day Avg. Volume115,694
Standard Deviation0.29
R-Squared0.16
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.84
Price to Sales (P/S)233.00
Price to Cash Flow (P/CF)2.20
P/FCF Ratio2.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-32.36
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.23
Forecast
1Y Price Target
$12.00Price Target Upside397.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Generation Bio News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GBIO FAQ
What was Generation Bio Co.’s price range in the past 12 months?
Generation Bio Co. lowest stock price was $3.05 and its highest was $7.35 in the past 12 months.
What is Generation Bio Co.’s market cap?
Currently, no data Available
When is Generation Bio Co.’s upcoming earnings report date?
Generation Bio Co.’s upcoming earnings report date is Nov 14, 2023 which is in 26 days.
How were Generation Bio Co.’s earnings last quarter?
Generation Bio Co. released its earnings results on Aug 02, 2023. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.483 by $0.013.
Is Generation Bio Co. overvalued?
According to Wall Street analysts Generation Bio Co.’s price is currently Undervalued.
Does Generation Bio Co. pay dividends?
Generation Bio Co. does not currently pay dividends.
What is Generation Bio Co.’s EPS estimate?
Generation Bio Co.’s EPS estimate is -$0.48.
How many shares outstanding does Generation Bio Co. have?
Generation Bio Co. has 65,928,505 shares outstanding.
What happened to Generation Bio Co.’s price movement after its last earnings report?
Generation Bio Co. reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.483. Following the earnings report the stock price went up 0.223%.
Which hedge fund is a major shareholder of Generation Bio Co.?
Among the largest hedge funds holding Generation Bio Co.’s share is Farallon Capital Management, L.L.C.. It holds Generation Bio Co.’s shares valued at N/A.
---
Generation Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (397.93% Upside)
$12.00 (397.93% Upside)
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.98%
12-Months-Change
Fundamentals
Return on Equity
-43.81%
Trailing 12-Months
Asset Growth
-3.37%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Generation Bio Co.
Generation Bio Co is a genetics medicine company which is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina related diseases.
---
Top 5 ETFs holding GBIO
Vanguard Total Stock Market ETF
$5.14M
Schwab U.S. Broad Market ETF
$111.00K
iShares Russell 3000 ETF
$67.23K
Vanguard Russell 3000 ETF
$10.22K
Fidelity Blue Chip Growth ETF
$4.67K
Up to five ETFs with an Outperform Smart Score that hold GBIO. The ETFs are listed according to market value of GBIO within the ETF
Abeona Therapeutics
―
Crispr Therapeutics AG
―
Editas Medicine
―
Sangamo Biosciences
―
---